1. Home
  2. GILD vs SPOT Comparison

GILD vs SPOT Comparison

Compare GILD & SPOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GILD
  • SPOT
  • Stock Information
  • Founded
  • GILD 1987
  • SPOT 2006
  • Country
  • GILD United States
  • SPOT Luxembourg
  • Employees
  • GILD N/A
  • SPOT N/A
  • Industry
  • GILD Biotechnology: Biological Products (No Diagnostic Substances)
  • SPOT Broadcasting
  • Sector
  • GILD Health Care
  • SPOT Consumer Discretionary
  • Exchange
  • GILD Nasdaq
  • SPOT Nasdaq
  • Market Cap
  • GILD 131.5B
  • SPOT 131.0B
  • IPO Year
  • GILD 1992
  • SPOT 2018
  • Fundamental
  • Price
  • GILD $104.54
  • SPOT $574.25
  • Analyst Decision
  • GILD Buy
  • SPOT Buy
  • Analyst Count
  • GILD 27
  • SPOT 29
  • Target Price
  • GILD $105.32
  • SPOT $562.82
  • AVG Volume (30 Days)
  • GILD 10.4M
  • SPOT 2.5M
  • Earning Date
  • GILD 04-24-2025
  • SPOT 04-29-2025
  • Dividend Yield
  • GILD 3.02%
  • SPOT N/A
  • EPS Growth
  • GILD N/A
  • SPOT N/A
  • EPS
  • GILD 0.38
  • SPOT 5.69
  • Revenue
  • GILD $28,754,000,000.00
  • SPOT $16,226,317,429.00
  • Revenue This Year
  • GILD $1.80
  • SPOT $18.23
  • Revenue Next Year
  • GILD $3.83
  • SPOT $15.48
  • P/E Ratio
  • GILD $275.11
  • SPOT $100.85
  • Revenue Growth
  • GILD 6.04
  • SPOT 18.31
  • 52 Week Low
  • GILD $62.07
  • SPOT $267.76
  • 52 Week High
  • GILD $119.96
  • SPOT $652.63
  • Technical
  • Relative Strength Index (RSI)
  • GILD 43.51
  • SPOT 53.20
  • Support Level
  • GILD $97.32
  • SPOT $539.66
  • Resistance Level
  • GILD $107.18
  • SPOT $577.81
  • Average True Range (ATR)
  • GILD 3.94
  • SPOT 35.08
  • MACD
  • GILD -0.45
  • SPOT 3.06
  • Stochastic Oscillator
  • GILD 41.42
  • SPOT 95.49

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

About SPOT Spotify Technology S.A.

Spotify is the leading global music streaming service provider, with nearly 700 million monthly active users and over 250 million paying subscribers, with the latter comprising the firm's premium segment. most of the firm's revenue and nearly all its gross profit come from the subscribers, who pay a monthly fee to access a very comprehensive music library that consists of most of the most popular songs ever recorded, including all from the major record labels. The firm also sells separate audiobook subscriptions and integrates podcasts within its standard music app. Podcast content is not exclusive and is typically free to access on other platforms. Ad-supported users can access a similar music catalog but cannot customize a similar on-demand experience.

Share on Social Networks: